The online version of this article (doi:10.1186/1471-230X-14-71) contains supplementary material, which is available to authorized users.
Dyax Corp designed and provided funding for the studies described in this article. Dr. Rubinstein has no conflicts to declare. Dr. Bousvaros reports personal fees from Dyax Corp, personal fees from Millennium pharmaceuticals, grants and personal fees from Merck pharmaceuticals, personal fees from Up to Date, personal fees from Imedex, non-financial support from Prometheus, non-financial support from Nutricia, personal fees from Cubist, outside the submitted work. Dr. Sheffer reports serving as a principle investigator for Dyax Corp. Leslie Stolz, PhD and Joseph Biedenkapp, PhD are full-time employees of Dyax Corp. Chris Stevens, MD is a consultant for Dyax Corp. The authors declare that they have no competing interests.
ER participated in the analysis and interpretation of data and reviewed and revised the article; LS participated in the conception and design, analysis and interpretation of data and reviewed and revised the article; AS participated in the conception and design, analysis and interpretation of data and reviewed and revised the article; CS participated in the conception and design, analysis and interpretation of data and reviewed and revised the article; AB participated in the analysis and interpretation of data and reviewed and revised the article; all authors approved the final article as submitted.
Hereditary angioedema (HAE) is characterized by unpredictable attacks of debilitating subcutaneous and mucosal edema. Gastrointestinal attacks are painful, of sudden onset and often mistaken for acute abdomen leading to unnecessary surgery. The purpose of this study was to analyze symptom presentation of gastrointestinal angioedema in pediatric and adult HAE patients.
Information collected during the clinical development of ecallantide for treatment of acute HAE attacks included affected anatomic location, accompanying symptoms, medical history, and pain assessments. Efficacy endpoints included Treatment Outcome Score (TOS, maximum score = 100; minimally important difference = 30), a point-in-time measure of treatment response, and time to treatment response.
Forty-nine percent of 521 HAE attacks only involved abdominal symptoms. The most commonly reported abdominal symptoms were distension (77%), cramping (73%) and nausea (67%). The most common pain descriptors were tender, tiring-exhausting, aching, cramping and sickening. White blood cell counts were elevated (>10 × 109/L) in 23% of attacks (mean ± SD: 15.1 ± 11.27 × 109/L). A high proportion of patients reported a history of abdominal surgery, including appendectomy (23%), cholecystectomy (16.4%), and hysterectomy (8.2%). Mean TOS at 4 hours post ecallantide was 77±33 versus 29±65 for placebo. Median time to significant symptom resolution was 165 minutes (95% CI 136, 167) for ecallantide versus >4 hours (95% CI 161, >4 hours) for placebo. Anaphylactic reactions occurred in 6 of the 149 treated patients.
HAE should be considered in the differential diagnosis of patients with recurrent discrete episodes of severe, unexplained crampy abdominal pain associated with nausea.
The data used in the analysis were gathered across multiple clinical trials conducted during the clinical development program for ecallantide. All of the studies were conducted using Good Clinical Practices (GCP) and in accordance with the ethical principles that have their origins in the Declaration of Helsinki. Each site that participated in the clinical trials obtained the appropriate IRB or Ethics Committee approval prior to enrolling any patients. All patients provided written informed consent prior to undergoing any study-related procedures. Pediatric patients provided written assent and their parents or guardians gave written informed consent.
Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, Kaplan A, Riedl M, Kirkpatrick C, Magerl M, Drouet C, Cicardi M: Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012, 33 (6): 145-156. 10.2500/aap.2012.33.3627. CrossRef
Nzeako UC, Longhurst HJ: Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol. 2012, 24 (4): 353-361. PubMed
Sheffer AL, Craig JM, Willms-Kretschmer K, Austen KF, Rosen FS: Histopathological and ultrastructural observations on tissues from patients with hereditary angioneurotic edema. J Allergy. 1971, 47 (5): 292-297. PubMed
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, Brown SG, Camargo CA, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006, 117 (2): 391-397. 10.1016/j.jaci.2005.12.1303. CrossRefPubMed
Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pursun E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, et al: International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010, 6 (1): 24-10.1186/1710-1492-6-24. CrossRefPubMedPubMedCentral
Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B: Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group. Allergy. 2012, 67 (2): 147-157. 10.1111/j.1398-9995.2011.02751.x. CrossRefPubMed
Craig T, Pursun EA, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J. 2012, 5 (12): 182-199. 10.1097/WOX.0b013e318279affa. CrossRefPubMedPubMedCentral
Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Riedl M: US hereditary angioedema association medical advisory board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol. 2013, 1 (5): 458-467. 10.1016/j.jaip.2013.07.002. CrossRef
Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, Khan D, Sheikh J, Weldon D, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D: A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013, 131 (6): 1491-1493. 10.1016/j.jaci.2013.03.034. e1425 CrossRefPubMed
DANOCRINE® [package insert]. 2011, New York, NY: Sanofi-Synthelabo Inc
CINRYZE® (C1 Esterase [Human]) package insert. 2014, Exton, PA: ViroPharma Biologics, Inc
Berinert® [C1 Esterase Inhibitor (Human)] package insert. 2014, CSL Behring GmbH
FIRAZYR® [package insert]. 2013, Lexington, MA: Shire Orphan Therapies, Inc
KALBITOR® (ecallantide)[package insert]. 2012, Burlington, MA: Dyax Corp
Gandhi PK, Gentry WM, Bottorff MB: Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy. 2012, 32 (10): 902-909. 10.1002/j.1875-9114.2012.01126. CrossRefPubMed
- Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency
Leslie E Stolz
Albert L Sheffer
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II